희귀유전질환심포지엄조직위원회
The Organizing Committee for Rare Genetic Diseases
PROFILE
박장환 Project Director
Current Status and Future Prospects of National Research Funding Investment in Gene Therapy R&D in Healthcare
In this presentation, we will discuss the current status of research funding in the healthcare R&D gene therapy field and promising technologies in the regenerative medicine field for the future
보건산업진흥원
Education
Hanyang University Ph.D. Medical Microbiology
Career & Experience
2023-present Korea Health Industry Development Institute (KHIDI) Advanced Regenerative Medicine
Project Director (PD)
1994-2023 Hanyang University Department of Microbiology, College of Medicine Professor
2011-2023 Hanyang University Graduate School of Biomedical Science & Engineering Professor
2017-2018 National Research Foundation of Korea Division of Drug Discovery and Development Director
2011-2013 Hanyang University Graduate School of Biomedical Science & Engineering Director of
Academic Affairs
2004-2005 Harvard University Neuroscience Lab, McLean Hospital Visiting Professor
5 representative research papers
-Role of UPF1-LIN28A interaction during early differentiation of pluripotent stem cells,
Nature Communications, 2024.
- Delivery of self-replicating messenger RNA into brain for the treatment of ischemic stroke,
Journal of Controlled Release, 2022.
- Messenger RNA/polymeric carrier nanoparticles for delivery of heme oxygenase-1 gene in the post-ischemic brain. Biomaterials Science, 2020.
- Dopamine neuron induction and neuroprotective effects of thyroid hormone derivatives. Scientific Reports, 2019.
- Efficient generation of dopamine neurons by synthetic transcription factor mRNAs. Molecular Therapy, 2017.
5 recently registered patents
- Generation of dopamine neurons using synthetic transcription factor mRNAs. Japan, 7435942, 2024.
- Preparation of neural stem cells (NSCs) with improved repair capacity using Lin28 expression. USA, 11339196, 2022.
- In vivo monitoring system for neural stem cell therapy based on neuronal differentiation specific surface antigen expression. Korea, 10-2315868, 2021.
- Astrocyte-specific nucleic acid aptamer and use thereof. Korea, 10-2218267, 2021.
- Novel derivatives of thyroid hormone and use of thereof. Korea, 10-2292894, 2021.
Giovanni Trolese vice president
Breaking Barriers: Advancing Rare Disease Treatments through Clinical Trials
In this presentation, we will discuss the current status of research funding in the healthcare R&D gene therapy field and promising technologies in the regenerative medicine field for the future
OPIS s.r.l. ( HQ )
Education
2015: Diploma in Strategic Management - CMI (Chartered Management Institute)
2012-2014: Master in Business Administration (MBA) - University of West London
1997-2003: Master of Life Science in Psychology (Laurea-5 years) - University of
Padova (Italy)
Current Position
Job Title: Vice President Strategic Development, OPIS Srl
Start Date: June 2021
- Responsible for the overall business development, marketing, and
commercial strategy of the Company at a global level
- Responsible for the global expansion of the Company from a strategic and
business level
- Develop high quality business strategies and plans, ensuring their
alignment with short-term and long-term objectives
- Drive the sales strategy and process to ensure quality and effective win
strategies in all proposals
- Oversee all operations and business activities to ensure they produce the
desired results and are consistent with the overall strategy and mission
Work Experience
2019 - 2021: Global Head of Business Development at OPIS Srl:
- Creating the Corporate and Business Development Strategy
- Leading Cross Functional Teams
- Reviewing and implementing the complete company approach to
Business
- Managing a Team of 15 people between BDM, Inside Sales and Proposal
Managers, Vendor Manager
- Identifying opportunities for new business as well as building upon
existing business
- Developing and implementing BD strategy with Biotech, Pharma and MD
Leaders
- Developing account plans for key strategic clients
- Developing account plans for regional businesses across the Globe
- Leading client strategy meetings
- Leading bid defense meetings
- Selling consulting services in Regulatory Affairs, Pharmacovigilance, Preclinical,
Full Service Phase I to Phase IV, EDC Proprietary System
- Building an active and engaged community of customers, prospects and
advocate with outbound business strategies
- Executing against targets identified with leadership team
- Being the face of the company at related networking events and
presentation
- Managing proposals and contract negotiation
2017 - 2019: Director of Business Development at PHARMASSIST CRO:
- Supporting the global expansion of a niche CRO (Contract Research
Organization) by strategically selling the services to Pharma companies
and CRO for Phase I-II-III
- Identifying opportunities for new business as well as building upon
existing business
- Developing and implementing BD strategy with Biotech, Pharma and MD
Leaders
FRM-WI-HRE001-01 Ver.00 03Apr2020 Page 2 of 3
- Developing account plans for key strategic clients
- Developing account plans for regional businesses across the Globe
- Delivering capability presentations
- Leading client strategy meetings
- Leading bid defense meetings
- Selling consulting services in Regulatory Affairs, Pharmacovigilance, Phase
II to Phase IV
- Building an active and engaged community of customers, prospects and
advocate with outbound business strategies
- Executing against targets identified with leadership team
- Being the face of the company at related networking events and
presentation
- Managing proposals and contract negotiation
2010 - 2013: Associate Director at RPS (Research Pharmaceutical Services) - PRA
International:
- Created and implemented Business Development in the Full Service and
Consultancy side for a mid-size CRO (Contract Research Organization)
- Led and support the company throughout 5 acquisitions processes
(Infociencia, Imerem, Therapharm, Warburg Pincus. KKR)
- Business Development for all company services to a wide range of both
new and existing clients across the Pharmaceutical industry in EMEA/
APAC: Mid-size Pharmaceuticals, Biotech, Medical Devices
- RFI and RFP for Full Services and Consultancy
- Offering consulting services in Regulatory Affairs, Pharmacovigilance and
QA, Data Management, Biostatistics, Phase I to Phase IV
- Business Development: creating a minimum of two new leads per week
and converting them into Bid Defence, Business Meetings, Conference
Calls, RFI, RFP.
- Developed account plans for key strategic clients
- Developed account plans for regional business across EMEA/APAC
- Delivered capability presentations
- Led client strategy meetings
- Led bid defense meetings
- Managed a Team of people distributed in Europe
- Coordinated the marketing initiatives in EMEA/APAC
Licenses/
Memberships
Italian: Mother tongue;
English: Fluent
French: Fluent
Spanish: Fluent
Japanese: Fluent Business Conversation
Mandarin Chinese: Fluent Business Conversation
Korean: Beginner
박소영 박사
부산대학교 생명시스템연구소
The Therapeutic Effect through DX2 Inhibition in Nicotine-induced Lung Cancer Progression
Small cell lung cancer (SCLC) is known to be closely related to smoking habit and most aggressive type of lung cancer. DX2, an alternative splicing product of AIMP2 and an inhibitor of p14/ARF, is stabilized by nicotine and promotes lung cancers by inducing HER2 and sonic hedgehog ligands. Therefore, inhibition of DX2 would be a very promising strategy for smoking-related cancers.
Education
▪ Sep. 2022 – present Post-Doctoral Researcher, Pusan National University.
▪ Sep. 2016 – Aug. 2022 Ph.D., Department of Integrated Biological Science, Pusan National University.
▪ Mar. 2013 – Aug. 2016 B.S., Department of Molecular Biology, Pusan National University.
Research Experiences
1. Kang SM, Seo S, Song EJ, Kweon O, Jo AH, Park S, Woo TG, Kim BH, Oh GT, Park BJ. “Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson-Gilford Progeria Syndrome.” Cells vol. 12,9 1232. 24 Apr. 2023, doi:10.3390/cells12091232
2. Kim BH, Woo TG, Kang SM, Park S, Park BJ. “Splicing Variants, Protein-Protein Interactions, and Drug Targeting in Hutchinson-Gilford Progeria Syndrome and Small Cell Lung Cancer.” Genes vol. 13,2 165. 18 Jan. 2022, doi:10.3390/genes13020165
3. Woo TG, Yoon MH, Kang SM, Park S, Cho JH, Hwang YJ, Ahn J, Jang H, Shin YJ, Jung EM, Ha NC, Kim BH, Kwon Y, Park BJ. “Novel chemical inhibitor against SOD1 misfolding and aggregation protects neuron-loss and ameliorates disease symptoms in ALS mouse model.” Communications biology vol. 4,1 1397. 15 Dec. 2021, doi:10.1038/s42003-021-02862-z
4. Cho JH, Park S, Kim S, Kang SM, Woo TG, Yoon MH, Lee H, Jeong M, Park YH, Kim H, Han YT, Suh YG, Kim BH, Kwon Y, Yun H, Park BJ. “RKIP Induction Promotes Tumor Differentiation via SOX2 Degradation in NF2-Deficient Conditions.” Molecular cancer research : MCR vol. 20,3 (2022): 412-424. doi:10.1158/1541-7786.MCR-21-0373
5. Kang SM, Yoon MH, Lee SJ, Ahn J, Yi SA, Nam KH, Park S, Woo TG, Cho JH, Lee J, Ha NC, Park BJ. “Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A.” Scientific reports vol. 11,1 9122. 27 Apr. 2021, doi:10.1038/s41598-021-88325-1
6. Kang SM, Yoon MH, Ahn J, Kim JE, Kim SY, Kang SY, Joo J, Park S, Cho JH, Woo TG, Oh AY, Chung KJ, An SY, Hwang TS, Lee SY, Kim JS, Ha NC, Song GY, Park BJ. “Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.” Communications biology vol. 4,1 5. 4 Jan. 2021, doi:10.1038/s42003-020-01540-w
7. Yoon MH, Kang SM, Lee SJ, Woo TG, Oh AY, Park S, Ha NC, Park BJ. “p53 induces senescence through Lamin A/C stabilization-mediated nuclear deformation.” Cell death & disease vol. 10,2 107. 6 Feb. 2019, doi:10.1038/s41419-019-1378-7
8. Cho JH, Oh AY, Park S, Kang SM, Yoon MH, Woo TG, Hong SD, Hwang J, Ha NC, Lee HY, Park BJ. “Loss of NF2 Induces TGFβ Receptor 1-mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome.” Molecular cancer therapeutics vol. 17,11 (2018): 2271-2284. doi:10.1158/1535-7163.MCT-17-1210
9. Park S, Oh AY, Cho JH, Yoon MH, Woo TG, Kang SM, Lee HY, Jung YJ, Park BJ. “Therapeutic Effect of Quinacrine, an Antiprotozoan Drug, by Selective Suppression of p-CHK1/2 in p53-Negative Malignant Cancers.” Molecular cancer research : MCR vol. 16,6 (2018): 935-946. doi:10.1158/1541-7786.MCR-17-0511
10. Oh AY, Jung YS, Kim J, Lee JH, Cho JH, Chun HY, Park S, Park H, Lim S, Ha NC, Park JS, Park CS, Song GY, Park BJ. “Inhibiting DX2-p14/ARF Interaction Exerts Antitumor Effects in Lung Cancer and Delays Tumor Progression.” Cancer research vol. 76,16 (2016): 4791-804. doi:10.1158/0008-5472.CAN-15-1025
백승태 교수
Neuropathology-Based Insights into Therapeutic Strategies for
DNM1L-Associated Neurodevelopmental Disorder
DNM1L, encoding the dynamin-related protein 1, is crucial for mitochondria and peroxisome division. Mutations in DNM1L are linked to epileptic encephalopathy, yet their functional impact remains unclear, limiting treatment options. Using cellular and animal models we revealed neuropathology-based insights into therapeutic strategies for DNM1L-related neurodevelopmental disorders
포항공과대학교
Education
2008-2012 Ph.D. Genetics and
Development
University of Texas Southwestern Medical Center, TX, USA
2005-2007 M.S. Microbiology Chungnam National University, South Korea
1995-1999 B.S. Biochemistry (Maj)
Psychology (Min)
Chungnam National University, South Korea
ACADEMIC TRAINING
2012-2017 Postdoctoral
fellow
Neuroscience The Rockefeller University, NY, USA
University of California San Diego, CA, USA
(Prof. Joseph G. Gleeson, M.D.)
2005-2008 Researcher Biotechnology Korea Research Institute of Bioscience and Biotechnology,
Functional genomics research center, South Korea
ACADEMIC APPOINTMENT
2017-Present Assistant, Associate Professor Department of Life Sciences, POSTECH, South Korea
2018-Present Adjunct Professor Yonsei University
PUBLICATIONS
1. Lee S, Kang MK, So KH, Jang R, Shin YW, Jang SS, Yoon JG, Kim S, Kim M, Chu K, Lee SK,
Kim KJ, Baek ST, Lim BC, Moon J. Broadening the scope of multigene panel analysis for adult
epilepsy patients. Epilepsia Open. 2024 Jul 1. doi: 10.1002/epi4.12993.
2. Kim TY, Roychaudhury A, Kim HT, Choi TI, Baek ST, Thyme SB, Kim CH. Impairments of
cerebellar structure and function in a zebrafish KO of neuropsychiatric risk gene znf536.
Translational Psychiatry. 2024 Feb 8;14(1):82. doi: 10.1038/s41398-024-02806-1.
3. Kim SH, Kwon SS, Park MR, Lee HA, Kim JH, Cha J, Kim S, Baek ST, Kim SH, Lee JS, Kim HD,
Choi JR, Lee ST*, Kang HC*. Detecting low-variant allele frequency mosaic pathogenic variants of
NF1, TSC2, and AKT3 genes from blood in patients with neurodevelopmental disorders. Journal of
Molecular Diagnostics. 2023 Aug;25(8):583-591. doi: 10.1016/j.jmoldx.2023.04.003.
4. Yun EJ, Kim D, Kim S, Hsieh JT, Baek ST*. Targeting Wnt/β-catenin-mediated upregulation of
oncogenic NLGN3 suppresses cancer stem cells in glioblastoma. Cell Death & Disease. 2023 Jul
13;14(7):423. doi: 10.1038/s41419-023-05967-x.
5. Ko B, Yoo JY, Yoo T, Choi W, Dogan R, Sung K, Um D, Lee SB, Kim HJ, Lee S, Baek ST, Park
SK, Paik SB, Kim TK, Kim JH*. Npas4-mediated dopaminergic regulation of safety memory
consolidation. Cell Reports. 2023 Jun 27;42(7):112678. doi: 10.1016/j.celrep.2023.112678.
6. Mun DJ, Goo BS, Suh BK, Hong JH, Woo Y, Kim SJ, Kim S, Lee SB, Won Y, Yoo JY, Cho E, Jang
EJ, Nhung TTM, Triet HM, An H, Lee H, Nguyen MD, Park SY, Baek ST, Park SK*. Gcap14 is a
microtubule plus-end-tracking protein coordinating microtubule-actin crosstalk during
neurodevelopment. Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2214507120. doi:
10.1073/pnas.2214507120.
7. Goo BS, Mun DJ, Kim S, Nhung TTM, Lee SB, Woo Y, Kim SJ, Suh BK, Park SJ, Lee HE, Park K,
Jang H, Rah JC, Yoon KJ, Baek ST, Park SY*, Park SK*. Schizophrenia-associated Mitotic Arrest
Deficient-1 (MAD1) regulates the polarity of migrating neurons in the developing neocortex.
Molecular Psychiatry. 2023 Feb;28(2):856-870. 10. doi: 10.1038/s41380-022-01856-5.
8. Kim YE, Kim YS, Lee HE, So KH, Choe Y, Suh BC, Kim JH, Park SK, Mathern GW, Gleeson JG,
Rah JC*, and Baek ST*. Reversibility and developmental neuropathology of linear nevus sebaceous
syndrome caused by dysregulation of the RAS-MAPK pathway. Cell Reports. 2023 Jan
31;42(1):112003. doi: 10.1016/j.celrep.2023.112003.
9. Kim SY, Lee S, Woo H, Han J, Ko YJ, Shim Y, Park S, Jang SS, Lim BC, Ko JM, Kim KJ, Cho A,
Kim H, Hwang H, Choi JE, Kim MJ, Moon J, Seong MW, Park SS, Choi SA, Lee JE, Kwon YS,
Sohn YB, Kim JS, Kim WS, Lee YJ, Kwon S, Kim YO, Kook H, Cho YG, Cheon CK, Kang KS,
Song MR, Kim YJ, Cha HJ, Choi HJ, Kee Y, Park SG, Baek ST, Choi M, Ryu DS, Chae JH*. The
Korean undiagnosed diseases program phase I: expansion of the nationwide network and the
development of long-term infrastructure. Orphanet Journal of Rare Diseases. 2022 Oct 8;17(1):372.
doi: 10.1186/s13023-022-02520-5.
10. Yun EJ*, Kim D, Hsieh JT, Baek ST*. Stanniocalcin 2 drives malignant transformation of human
glioblastoma cells by targeting SNAI2 and Matrix Metalloproteinases. Cell Death Discov. 2022 Jul
5;8(1):308. doi: 10.1038/s41420-022-01090-6.
11. Lee S, Nam M, Lee AR, Baek ST, Kim MJ, Kim JS, Kong AH, Lee M, Lee SJ, Kim SY, Kim DU,
Hoe KL*. Knockdown of vps54 aggravates tamoxifen-induced cytotoxicity in fission yeast. Genomics
& Informatics. 2021 Dec;19(4):e39. doi: 10.5808/gi.21049.
12. Yun EJ*, Kim S, Hsieh JT, Baek ST*. Wnt/β-catenin signaling pathway induces autophagy-mediated
temozolomide-resistance in human glioblastoma. Cell Death & Disease. 2020 Sep 17;11(9):771. doi:
10.1038/s41419-020-02988-8.
13. Wenderski W, Wang L, Krokhotin A, Walsh JJ, Li H, Shoji H, Ghosh S, George RD, Miller EL, Elias
L, Gillespie MA, Son EY, Staahl BT, Baek ST, Stanley V, Moncada C, Shipony Z, Linker SB,
Marchetto MCN, Gage FH, Chen D, Sultan T, Zaki MS, Ranish JA, Miyakawa T, Luo L, Malenka
RC, Crabtree GR, Gleeson JG*. Loss of the neural-specific BAF subunit ACTL6B relieves repression
of early response genes and causes recessive autism. Proc Natl Acad Sci U S A. 2020 May
5;117(18):10055-10066. doi: 10.1073/pnas.1908238117.
14. Woo Y, Kim SJ, Suh BK, Kwak Y, Jung HJ, Nhung TTM, Mun DJ, Hong JH, Noh SJ, Kim S, Lee A,
Baek ST, Nguyen MD, Choe Y, Park SK*. Sequential phosphorylation of NDEL1 by the DYRK2-
GSK3β complex is critical for neuronal morphogenesis. Elife. 2019 Dec 9;8:e50850. doi:
10.7554/eLife.50850.
15. Kim YE and Baek ST*. Neurodevelopmental Aspects of RASopathies. Molecules and Cells. 2019
Jun 30;42(6):441-447. doi: 10.14348/molcells.2019.0037.
16. Yun EJ, Lin CJ, Dang A, Hernandez E, Guo J, Chen WM, Allison J, Kim N, Kapur P, Brugarolas J,
Wu K, He D, Lai CH, Lin H, Saha D, Baek ST*, Chen BPC*, Hsieh JT*. Down-regulation of human
DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation.
Clinical Cancer Research. 2019 Jul 15;25(14):4542-4551. doi: 10.1158/1078-0432.CCR-18-3004.
17. Schaffer AE, Breuss MW, Caglayan AO, Al-Sanaa N, Al-Abdulwahed HY, Kaymakçalan H, Yılmaz
C, Zaki MS, Rosti RO, Copeland B, Baek ST, Musaev D, Scott EC, Ben-Omran T, Kariminejad A,
Kayserili H, Mojahedi F, Kara M, Cai N, Silhavy JL, Elsharif S, Fenercioglu E, Barshop BA, Kara B,
Wang R, Stanley V, James KN, Nachnani R, Kalur A, Megahed H, Incecik F, Danda S, Alanay Y,
Faqeih E, Melikishvili G, Mansour L, Miller I, Sukhudyan B, Chelly J, Dobyns WB, Bilguvar K,
Jamra RA, Gunel M, Gleeson JG*. Biallelic loss of human CTNNA2, encoding αN-catenin, leads to
ARP2/3 complex overactivity and disordered cortical neuronal migration. Nature Genetics. 2018
Aug;50(8):1093-1101. doi: 10.1038/s41588-018-0166-0.
18. Baek ST, Copeland B, Yun EJ, Kwon SK, Guemez-Gamboa A, Schaffer AE, Kim S, Kang HC, Song
S, Mathern GW, Gleeson JG*. An AKT3-FOXG1-Reelin Network Underlies Defective Migration in
Human Focal Malformations of Cortical Development. Nature Medicine. 2015 Dec;21(12):1445-54.
doi: 10.1038/nm.3982.
19. Kang HC, Baek ST, Song S, Gleeson JG. Clinical and genetic aspects of the segmental overgrowth
spectrum due to somatic mutations in PIK3CA. Journal of Pediatrics. 2015 Nov;167(5):957-62. doi:
10.1016/j.jpeds.2015.07.049.
20. Conti V, Pantaleo M, Barba C, Baroni G, Mei D, Buccoliero AM, Giglio S, Giordano F, Baek ST,
Gleeson JG, Guerrini R*. Focal dysplasia of the cerebral cortex and infantile spasms associated with
somatic 1q21.1-q44 duplication including the AKT3 gene. Clinical Genetics. 2015 Sep;88(3):241-7.
doi: 10.1111/cge.12476.
21. Yun EJ, Baek ST, Xie D, Tseng SF, Dobin T, Zhang L, Sun H, Xiao G, He D, Kittler R, Hernandez
E, Zhou J, Yang J, Hsieh JT*. DAB2IP regulates cancer stem cell phenotypes through modulating
stem cell factor receptor and ZEB1. Oncogene. 2015 May 21;34(21):2741-52. doi:
10.1038/onc.2014.215.
22. Baek ST*, Kerjan G*, Bielas SL, Lee JE, Fenstermaker AG, Novarino G, Gleeson JG*. Off-Target
Effect of doublecortin Family shRNA on Neuronal Migration Associated with Endogenous
MicroRNA Dysregulation. Neuron. 2014 Jun 18;82(6):1255-62. doi: 10.1016/j.neuron.2014.04.036.
(* equal contribution)
23. Novarino G, Baek ST, Gleeson JG*. The sacred disease: the puzzling genetics of epileptic disorders.
Neuron. 2013 Oct 2;80(1):9-11. doi: 10.1016/j.neuron.2013.09.019.
24. Baek ST, Gibbs EM, Gleeson JG and Mathern GW. Hemimegalencephaly, a paradigm for somatic
postzygotic neurodevelopmental disorders. Current Opinion in Neurology. 2013 Apr;26(2):122-7.
doi: 10.1097/WCO.0b013e32835ef373.
25. Acharya A, Baek ST*, Huang G*, Eskiocak B, Goetsch S, Sung CY, Banfi S, Sauer MF, Olsen GS,
Duffield JS, Olson EN, Tallquist MD. The bhlh transcription factor Tcf21, is required for lineagespecific
EMT of cardiac fibroblast progenitors. Development. 2012 Jun;139(12):2139-2149. doi:
10.1242/dev.079970. (* equal contribution) [Research Highlight. Development. 2012]
26. Baek ST and Tallquist MD. Nf1 limits epicardial derivative expansion by regulating epithelial to
mesenchymal transition and proliferation. Development. 2012 Jun;139(11):2040-2049. doi:
10.1242/dev.074054.
27. Smith CL, Baek ST, Sung CY, Tallquist MD. Epicardial-derived cell epithelial to mesenchymal
transition and fate specification require PDGF receptor signaling. Circulation Research. 2011 Jun
10;108(12):e15-26. doi: 10.1161/CIRCRESAHA.110.235531. [Best Manuscript Award. Circ Res.
2011]
28. Acharya A, Baek ST, Banfi S, Eskiocak B, Tallquist MD. Efficient inducible Cre-mediated
recombination in Tcf21 cell lineages in the heart and kidney. Genesis. 2011 Nov;49(11):870-722. doi:
10.1002/dvg.20750.
29. Kim DU, Hayles J, Kim D, Wood V, Park HO, Won M, Yoo HS, Duhig T, Nam M, Palmer G, Han S,
Jeffery L, Baek ST, Lee H, Shim YS, Lee M, Kim L, Heo KS, Noh EJ, Lee AR, Jang YJ, Chung KS,
Choi SJ, Park JY, Park Y, Kim HM, Park SK, Park HJ, Kang EJ, Kim HB, Kang HS, Park HM, Kim
K, Song K, Song KB, Nurse P, Hoe KL. Analysis of a genome-wide set of gene deletions in the
fission yeast Schizosaccharomyces pombe. Nature Biotechnology. 2010 Jun;28(6):617-23. doi:
10.1038/nbt.1628.
30. Heo KS, Ryoo SW, Kim L, Nam M, Baek ST, Lee H, Lee AR, Park SK, Park Y, Myung CS, Kim
DU, Hoe KL. Cl(-)-Channel Is Essential For LDL-induced Cell Proliferation via the Activation of
Erk1/2 and PI3K/Akt and the Upregulation of Egr-1 in Human Aortic Smooth Muscle Cells.
Molecules and Cells. 2008 Nov 30;26(5):468-73.
31. Heo KS, Kim DU, Kim L, Nam M, Baek ST, Park SK, Park Y, Myung CS, Hwang SO, Hoe KL.
Activation of PKCbeta(II) and PKCtheta is essential for LDL-induced cell proliferation of humanaortic smooth muscle cells via Gi-mediated Erk1/2 activation and Egr-1 upregulation. Biochem
Biophys Res Commun. 2008 Mar 28;368(1):126-31. doi: 10.1016/j.bbrc.2008.01.050.
32. Baek ST, Han S, Nam M, Kim YD, Lee HJ, Heo KS, Lee H, Ahn SK, Lee M, Park SK, Maeng PJ,
Park Y, Lee S, Kim DU, Kim D, Hoe KL. Genome-wide Identification of Haploinsufficiency in
Fission Yeast. J Microbiol Biotechnol. 2008 Jun;18(6):1059-63.
33. Baek ST, Kim DU, Han S, Woo IS, Nam M, Kim L, Heo KS, Lee H, Hwang H, Choi SJ, Won M,
Lee M, Park SK, Lee S, Kwon HJ, Maeng PJ, Park HM, Park Y, Kim D, Hoe KL Genome-wide druginduced
haploinsufficient screening of fission yeast for identification of hydrazinocurcumin targets. J
Microbiol Biotechnol. 2008 Feb;18(2):263-9.
34. Heo KS, Kim DU, Ryoo S, Nam M, Baek ST, Kim L, Park SK, Myung CS, Hoe KL. PPARgamma
activation abolishes LDL-induced proliferation of human aortic smooth muscle cells via SODmediated
down-regulation of superoxide. Biochem Biophys Res Commun. 2007 Aug
10;359(4):1017-23. doi: 10.1016/j.bbrc.2007.06.006.